Foundayo (orforglipron) is a non-peptide, small-molecule GLP-1 receptor agonist that does not rely on SNAC technology for absorption
Its usually the small things
Hims & Hers Health (HIMS) stock soared Monday, ending the day up over 40% as Danish drugmaker Novo Nordisk (NVO) said it had agreed to distribute its products through the Hims platform, ending a longstanding feud between the companies
This astrocyte-neuron metabolic coupling sustains continuous aerobic glycolysis and offers a potential treatment strategy for AD
Calcium D-glucarate may increase the body's excretion of certain medications
Virta Health Announces First-of-its-Kind Peer-Reviewed Study Proving Its Approach Is an Effective Off-Ramp From GLP-1s for Sustained Weight Loss Company builds on nearly 10 years of GLP-1 experience, expanding its Sustainable Weight Loss solution to deliver medication-free and medication-assisted weight loss Virta Health has released first-of-its-kind, peer-reviewed data demonstrating the companys approach to personalized nutrition therapy results in sustained weight loss after the discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1s), including Ozempic
